Construction and Validation of a Risk Prediction Model for Secondary Vertebral Fracture in Patients With Osteoporotic Vertebral Compression Fractures After Percutaneous Vertebroplasty
Recruiting
- Conditions
- Prediction ModelOsteoporotic Vertebral Fracture
- Registration Number
- NCT06172179
- Brief Summary
"Retrospectively collecting clinical data from post-PVA (Percutaneous Vertebroplasty) patients, recording incidences of secondary vertebral fractures, and conducting statistical analysis to create a risk prediction model for recurrent fractures."
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Meets the diagnostic criteria for primary osteoporosis as per the Osteoporosis Diagnosis and Treatment Guidelines (2022);
- No history of high-energy trauma;
- Patient complains of pain in the lumbar region, confirmed by MRI showing a newly developed vertebral fracture from T5 to L5 (i.e., MRI shows low signal on T1 and high or slightly high signal on T2);
- Has undergone Percutaneous Vertebroplasty (PVA) treatment.
Exclusion Criteria
- Incomplete imaging or medical record data;
- History of spinal surgeries other than PVA;
- Pre-existing symptoms of spinal cord compression or nerve root injury;
- Patients undergoing PVA treatment due to conditions such as tumors, vascular malformations, infections, or symptomatic Schmorl's nodes;
- Chronic conditions like Kummell's disease or non-union of old fractures;
- Concurrent vertebral burst fractures;
- Diagnosis of central nervous system diseases such as dementia or stroke before or during the follow-up period post-PVA procedure;
- History of violent trauma after PVA procedure.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method secondary vertebral fractures 2 years post-operative Recording the secondary vertebral fractures
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms contribute to secondary vertebral fractures after percutaneous vertebroplasty in osteoporotic patients?
How does the risk prediction model from NCT06172179 compare to existing tools for forecasting vertebral fracture recurrence in osteoporosis?
Which biomarkers are associated with increased risk of secondary vertebral fractures following percutaneous vertebroplasty?
What are the most effective strategies for managing and preventing secondary vertebral fractures in post-vertebroplasty patients with osteoporosis?
Are there specific drug classes or combination therapies that show promise in reducing secondary vertebral fracture risk after percutaneous vertebroplasty for osteoporotic compression fractures?
Trial Locations
- Locations (1)
Sun Yat-sen memorial hospital
🇨🇳Guangzhou, Guangdong, China
Sun Yat-sen memorial hospital🇨🇳Guangzhou, Guangdong, ChinaChunhai Li, MDContact18602079796lichhai@mail.sysu.edu.cnhanwen cheng, MasterContact19541080926chenghw3@mail2.sysu.edu.cn